Loading
companiesCompany
Idera Pharmaceuticals
Idera was a Cambridge biotech whose injected TLR9 agonist tilsotolimod, given into tumours with ipilimumab, failed a phase 3 trial in anti-PD-1-refractory melanoma in 2021.
Also called: Idera Pharmaceuticals, Inc.IderaAceragen
Overview
Idera Pharmaceuticals, founded in 1989 and based in Cambridge, Massachusetts, developed oligonucleotide Toll-like receptor agonists. Its intratumoural TLR9 agonist tilsotolimod was tested with ipilimumab in the phase 3 ILLUMINATE-301 trial in melanoma that had progressed on anti-PD-1 therapy and did not improve response or survival. The company merged with Aceragen in 2022 and later wound down. Its trials remain on ClinicalTrials.gov under Idera as lead sponsor.
Similar pages
- CompanyPregLem
- CompanyHiberCell
Shares Pivotal (registrational) trial, Clinical trial, Melanoma.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals